ROCHESTER, N.Y., Nov. 28 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , a leading developer of image-based biomarker solutions, announced today that the U.S. Patent Office has issued VirtualScopics’ patent titled “Method and System for Automatic Identification and Quantification of Abnormal Anatomical Structures in Medical Images” (U.S. Patent Number 7,103,224).
The innovation covered by this patent allows VirtualScopics to use both statistical and expert knowledge to measure a wide variety of abnormalities, from multiple sclerosis lesions to bone marrow edema, with extremely high precision - in one study demonstrating a 90% reduction in observer variability relative to manual measurement. This enables VirtualScopics’ customers to use smaller patient populations in their trials, enabling them to realize lower costs and accelerated time to market.
“One of our key differentiators is our ability to use automated systems to reduce the variability in our measurements,” said Dr. Edward Ashton, chief scientific officer of VirtualScopics and the inventor.
“We have made great progress in the automation of our image analysis algorithms. This automation not only significantly reduces variability but greatly increases our operating efficiency, both of which are of great benefit to our customers,” said Jeff Markin, president and CEO of VirtualScopics. “We are very proud of the growing portfolio of intellectual property developed by Dr. Ashton and the other scientists within the company.”
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Tim Ryan Bagatelle-Black Public Relations Trout Group Investor Relations 661/263-1842 212 477 9007 x24 tracy@bagatelleblack.comryan@troutgroup.com
VirtualScopics, Inc.
CONTACT: Tracy Bagatelle-Black of Bagatelle-Black Public Relations,+1-661-263-1842, or tracy@bagatelleblack.com; or Tim Ryan of Trout GroupInvestor Relations, +1-212-477-9007, ext. 24, or ryan@troutgroup.com, bothfor VirtualScopics, Inc.
Web site: http://www.virtualscopics.com//
